Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Showing public results only.
AI Financial has a real ALT5 fintech platform with $24.8 million of FY2025 revenue and $3.5 billion of disclosed 2025 transaction volume, but its current equity story is dominated by WLFI token volatility, a $344.5 million net loss, a working-capital deficit,
OpenSoFiUSD is the first U.S. national-bank issued stablecoin available inside a banking app. The bull case is distribution plus settlement; the proof gate is usage, enterprise adoption, and financial contribution.
OpenQ2 Holdings reported FY2025 revenue of $794.8 million, Q1 2026 revenue of $216.5 million, FY2025 operating cash flow of $201.5 million and Q1 2026 net income of $26.6 million. The thesis depends on banking software demand, subscription durability, margin expan
OpenMercadoLibre's Q1 2026 TPV was about 4.6x marketplace GMV, showing that Mercado Pago is more than a checkout layer. Amazon has the larger global machine, but official filings do not show a comparable disclosed Latin America fintech flywheel.
OpenAffirm is scaling GMV and has moved into GAAP operating profitability, but the stock thesis still depends on credit discipline, funding access, partner concentration, regulation and whether Card, wallets and international expansion preserve unit economics.
OpenAEMD is not a revenue story yet. It is a clinical-stage Hemopurifier bet with FDA Breakthrough Device designations, an Australian oncology trial, a going-concern warning, reverse splits, warrant mechanics and a cash balance that makes every new data point matt
OpenSenmiao Technology is a very high risk China ride-hailing auto-services microcap. The filings show a small post-disposal operating base, continuing losses, material weaknesses, Nasdaq compliance pressure and potentially heavy dilution mechanics.
OpenAIFU still has a large China insurance distribution platform, with 42,170 registered agents and 313 sales outlets, but the 2025 Form 20-F shows a severe revenue and asset-quality reset before a 2026 acquisition added dark tea inventory, heavy share issuance an
OpenFirefly Neuroscience pairs an FDA-cleared Evoke EEG/ERP workflow, more than 85 active U.S. clinical sites and a 191,000-record brain-data set with a harder financial reality: Q1 2026 revenue was only $485,000, cash was $3.1 million before subsequent financings
OpenAEON is trying to turn ABP-450 into a U.S. therapeutic BOTOX biosimilar, but the current setup combines FDA-pathway optionality with no commercial revenue, going-concern language, a short runway, listing pressure and heavy Daewoong concentration.
OpenA $4.5 million revenue base, a $47.4 million net loss, $25.2 million of cash, 132 Texas homes, and an $83.0 million related-party New Energy transaction make AEI a filing-reader's special situation rather than a simple real estate stock.
OpenAntelope Enterprise has a Nasdaq listing, China livestream e-commerce revenue, Bitcoin financing, fresh share issuance, and a planned energy-supply launch. The catch is the filed operating base: $60.8 million of transition-period revenue produced just $131,000
OpenAddex has real allosteric-modulator science, but the public-company story now turns on CHF 1.6 million of year-end cash, a delayed 2025 Form 20-F, chronic-cough preclinical data, dipraglurant repositioning, and a 20% Neurosterix option.
OpenAdvanced Biomed has historical cancer-diagnostics technology, but the latest filings show no product revenue, a reverse split, a short-term loan, a subsidiary divestiture, and an April 2026 pivot into AI.
Open